Picture of Arch Biopartners logo

ARCH — Arch Biopartners Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+16.16%
3m-10.82%
6m-3.6%
1yr+153.13%
Volume Change (%)
10d/3m-26.38%
Price vs... (%)
52w High-41.51%
50d MA-5.51%
200d MA-8.86%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin16.13%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for ARCH

Arch Biopartners Inc (CVE:ARCH): buy, sell or hold? background image

Arch Biopartners Inc (CVE:ARCH): buy, sell or hold?

Shares in Arch Biopartners Inc (CVE:ARCH) are currently trading close to a 52 week high, with the share price up by around 4.83% - to 1.52 - over the past week. On a one-month basis, the Arch Biopartners Inc price has risen by 20.6%. F...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 202230th Sep 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Arch Biopartners EPS forecast chart

Profile Summary

Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

Directors

Last Annual
September 30th, 2021
Last Interim
March 31st, 2022
Incorporated
November 13th, 2003
Public Since
October 9th, 1996
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconTSX Venture Exchange
Shares in Issue
62,330,292

ARCH Share Price Performance

Upcoming Events for ARCH

Similar to ARCH

Picture of Advanced Proteome Therapeutics logo

Advanced Proteome Therapeutics

ca flag iconTSX Venture Exchange

Picture of Alpha Cognition logo

Alpha Cognition

ca flag iconTSX Venture Exchange

Picture of biOasis Technologies logo

biOasis Technologies

ca flag iconTSX Venture Exchange

Picture of Ceapro logo

Ceapro

ca flag iconTSX Venture Exchange

Picture of Claritas Pharmaceuticals logo

Claritas Pharmaceuticals

ca flag iconTSX Venture Exchange

FAQ

Or unlock with your email

Or unlock with your email